Loomis, Sayles & Company
IPXL

Loomis, Sayles & Company’s Impax Laboratories, Inc. IPXL Stock Holding History

Loomis, Sayles & Company’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-231
Closed -$5K – 1152
2016
Q3 		$5K Sell
231
-529,161
-100% -$14.2M ﹤0.01% 897
2016
Q2 		$15.3M Sell
529,392
-20,037
-4% -$653K 0.04% 341
2016
Q1 		$17.6M Sell
549,429
-2,235
-0.4% -$78.6K 0.05% 306
2015
Q4 		$23.6M Buy
551,664
+60,163
+12% +$2.4M 0.07% 228
2015
Q3 		$17.3M Buy
491,501
+5,442
+1% +$245K 0.05% 320
2015
Q2 		$22.3M Buy
486,059
+59,908
+14% +$2.84M 0.06% 294
2015
Q1 		$20M Sell
426,151
-86,044
-17% -$3.42M 0.06% 336
2014
Q4 		$16.2M Buy
512,195
+57,872
+13% +$1.69M 0.05% 400
2014
Q3 		$10.8M Sell
454,323
-178,779
-28% -$4.58M 0.03% 477
2014
Q2 		$19M Buy
+633,102
New +$17.1M 0.05% 371

Other funds holding IPXL

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Loomis, Sayles & Company's IPXL Position: Q4 2016 in Review

Loomis, Sayles & Company sold out of Impax Laboratories, Inc. (IPXL) in Q4 2016, closing a stake of 231 shares — an estimated $5K sold.

Loomis, Sayles & Company first reported a position in IPXL in Q2 2014 and held it in 10 quarters. The position peaked at $23.6M in Q4 2015. 198 funds tracked by Wall St. Rank hold IPXL as of Q4 2016.

  • Loomis, Sayles & Company reported no remaining Impax Laboratories, Inc. position as of Q4 2016 after selling out during the quarter.
  • Loomis, Sayles & Company sold 231 Impax Laboratories, Inc. shares in Q4 2016, an estimated $5K.
  • Loomis, Sayles & Company first reported a position in Impax Laboratories, Inc. in Q2 2014 and held it in 10 quarters.
  • Loomis, Sayles & Company's Impax Laboratories, Inc. position peaked at $23.6M in Q4 2015.
  • 198 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2016.

Based on Loomis, Sayles & Company's 13F filing for Q4 2016, filed 14 Feb 2017.